AU5429699A - Drug targeting - Google Patents

Drug targeting

Info

Publication number
AU5429699A
AU5429699A AU54296/99A AU5429699A AU5429699A AU 5429699 A AU5429699 A AU 5429699A AU 54296/99 A AU54296/99 A AU 54296/99A AU 5429699 A AU5429699 A AU 5429699A AU 5429699 A AU5429699 A AU 5429699A
Authority
AU
Australia
Prior art keywords
drug targeting
targeting
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54296/99A
Inventor
David Blake
Declan Naughton
Ian Stratford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THERAMARK Ltd
Original Assignee
THERAMARK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9818027.6A external-priority patent/GB9818027D0/en
Priority claimed from GBGB9818156.3A external-priority patent/GB9818156D0/en
Application filed by THERAMARK Ltd filed Critical THERAMARK Ltd
Publication of AU5429699A publication Critical patent/AU5429699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
AU54296/99A 1998-08-19 1999-08-19 Drug targeting Abandoned AU5429699A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9818027.6A GB9818027D0 (en) 1998-08-19 1998-08-19 Drug targeting I
GB9818027 1998-08-19
GB9818156 1998-08-20
GBGB9818156.3A GB9818156D0 (en) 1998-08-20 1998-08-20 Drug targeting
PCT/GB1999/002606 WO2000010610A2 (en) 1998-08-19 1999-08-19 Drug targeting

Publications (1)

Publication Number Publication Date
AU5429699A true AU5429699A (en) 2000-03-14

Family

ID=26314233

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54296/99A Abandoned AU5429699A (en) 1998-08-19 1999-08-19 Drug targeting

Country Status (2)

Country Link
AU (1) AU5429699A (en)
WO (1) WO2000010610A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2369572A (en) 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
CA2430010A1 (en) 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
CA2511582C (en) * 2003-02-06 2012-01-24 Dompe S.P.A. 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them
DE102004025535A1 (en) * 2004-05-25 2005-12-22 Bayer Healthcare Ag Combination of salts of o-acetylsalicylic acid and alpha-glucosidase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988057B1 (en) * 1997-02-11 2003-08-27 The Victoria University Of Manchester Bioreductive conjugates for drug targeting

Also Published As

Publication number Publication date
WO2000010610A3 (en) 2000-06-02
WO2000010610A2 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
AU1225000A (en) Combined pharmaceutical estrogen-androgen-progestin
AU5259100A (en) Medicament
AU4357800A (en) Intracellular pharmaceutical targeting
AU3342599A (en) Delivery catheter
AU3733399A (en) Drug composites
AU1203501A (en) Enhanced herbicides
AU3904099A (en) Drug delivery module
AU2955200A (en) Cannula
AU2212300A (en) Delivery vault
AU3999699A (en) Targeted liposomal drug delivery system
AU1409100A (en) Drugs
AU3837999A (en) Drug delivery device
AU1645700A (en) Oenothein medicaments
AU2001232244A1 (en) Drug comprising combination
AU4064699A (en) Insecticide
AU1688099A (en) Pharmaceutical preparation
AU2214199A (en) Therapeutic liposome-encapsulated immunomodulators
AU5429699A (en) Drug targeting
AU2965199A (en) Medicine mini-chest
AU4726299A (en) Drug dispenser
AU1752101A (en) Medicament cartridge
AU5184599A (en) Pharmaceutical compounds
AU2279800A (en) Pharmaceutical preparation
AU4504201A (en) Drug preparations
AU7087198A (en) Medication dispenser

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase